Previous 10 | Next 10 |
Immatics N.V. (IMTX +10.2%) has recorded the biggest gain since May after announcing an agreement with Bristol Myers Squibb (NYSE:BMY) for the licensing, development, and commercialization of the company’s TCR Bispecific candidate IMA401. Per the terms, Immatics (NASDAQ:IMTX) will...
Galera Therapeutics (NASDAQ:GRTX) +138% announces primary endpoint met statistical significance in corrected topline efficacy data of phase 3 ROMAN trial of avasopasem. Nuverra Environmental Solutions (NYSE:NES) +33%. Terminix Global Holdings (NYSE:TMX) +25%. MIND Technology (NASDAQ:MIND...
Bristol Myers Squibb secures global exclusive license to Immatics’ TCR bispecific program IMA401; companies will collaborate on development with Immatics retaining a co-promotion option in the US Immatics to receive upfront payment of $150 million and additional milestone p...
Interim data update at SITC for ongoing ACTe ngine ® IMA203 trial targeting PRAME demonstrated clinical responses a cross multiple solid tumor types during dose escalation phase Immatics to i nitiate three expansio...
Company to host conference call on Tuesday, November 9 at 8:30 am EST Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients ...
Houston, Texas and Tuebingen, Germany, November 1, 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the ...
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Adaptimmune Therapeutics has a diverse pipeline focused on TCR-engineered T cells. Their most advanced candidate, afamitresgene autoleucel, will likely receive approval. Current valuation is fair given their market cap and pipeline, but longer-term outlook remains bullish. F...
ACTengine ® patient recruitment remains on track ; a s of en d of July, a total of 2 7 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeli...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...